ArticleScientific reports2025
Integrated transcriptomics and metabolomics studies reveal the therapeutic effects of Astragalus polysaccharides on cancer cachexia muscle atrophy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Proteomics- and Metabolomics-Based Investigation of the Effects ofAnimals : an open access journal from MDPI · 2026Article
- From homeostasis to pathology, organelle-specific autophagy in skeletal muscle: a PRISMA-ScR scoping review.Frontiers in physiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cancer cachexia (CC) is a condition causing significant muscle loss in advanced cancer patients, severely impacting their quality of life and life expectancy. The autophagy-lysosome system is a key pathway in muscle depletion in CC, but targeted therapies are lacking. This study investigates how Astragalus polysaccharides (APS) from the traditional Chinese herb Astragalus membranaceus alleviate muscle wasting in CC mice. Mice were divided into control, model, and APS high-dose groups. Results show high-dose APS significantly improved grip strength and muscle fiber cross-sectional area in CC mice. Transcriptomic analysis revealed differentially expressed genes (DEGs) enriched in autophagy and mitochondrial autophagy pathways. Electron microscopy showed APS reduced autophagic vesicles and protected muscle and mitochondria. Metabolomic analysis indicated APS regulates the expression of nitric oxide synthase (NOS). APS protects against muscle wasting in CC by suppressing excessive autophagy and reducing the expression of NOS, suggesting it as a potential therapeutic agent for mitigating muscle depletion in cancer cachexia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.